Cybin (CYBN) Stock Analysis

What Cybin does

Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.

Key metrics

ETFs linked to CYBN

Broad-market and Healthcare sector ETFs an investor holding Cybin is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CYBN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Cybin?

Cybin trades under the ticker CYBN on AMEX.

Which exchange is CYBN listed on?

CYBN is listed on AMEX.

What sector does Cybin operate in?

Cybin is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CYBN in a portfolio?

PortView shows CYBN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.